Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

38.47USD
24 May 2019
Change (% chg)

$0.68 (+1.80%)
Prev Close
$37.79
Open
$37.70
Day's High
$38.65
Day's Low
$37.68
Volume
2,036,170
Avg. Vol
1,846,076
52-wk High
$41.00
52-wk Low
$29.96

Latest Key Developments (Source: Significant Developments)

Late-Breaking Trial Data Highlight Continued Clinical Success Of Boston Scientific Emblem™ S-Icd System
Saturday, 11 May 2019 

May 10 (Reuters) - Boston Scientific Corp ::LATE-BREAKING TRIAL DATA HIGHLIGHT CONTINUED CLINICAL SUCCESS OF BOSTON SCIENTIFIC EMBLEM™ S-ICD SYSTEM.BOSTON SCIENTIFIC CORP - DATA DEMONSTRATED S-ICD THERAPY HAD A COMPLICATION-FREE RATE OF 95.8% AT 30 DAYS POST-PROCEDURE.BOSTON SCIENTIFIC CORP - DATA DEMONSTRATED S-ICD THERAPY HAD A HIGH CONVERSION EFFICACY (99.2%) OF INDUCED VENTRICULAR FIBRILLATION RATES.BOSTON SCIENTIFIC CORP - FINAL RESULTS OF UNTOUCHED STUDY WILL BE REPORTED AFTER 18-MONTHS OF PATIENT FOLLOW-UP.  Full Article

Boston Scientific Receives FDA Approval For Lotus Edge Aortic Valve System
Wednesday, 24 Apr 2019 

April 23 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES FDA APPROVAL FOR LOTUS EDGE™ AORTIC VALVE SYSTEM.BOSTON SCIENTIFIC CORP - COMMENCED A CONTROLLED LAUNCH OF VALVE SYSTEM IN EUROPE IN MARCH.BOSTON SCIENTIFIC CORP - EXPECTS TO BEGIN A CONTROLLED LAUNCH OF VALVE SYSTEM IN U.S. IN COMING WEEKS..  Full Article

Boston Scientific Says Disappointed By FDA’s Decision On Premarket Approval Applications For Uphold Lite Vaginal Support System, Xenform Soft Tissue Repair Matrix
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC - DISAPPOINTED BY FDA’S DECISION ON PREMARKET APPROVAL APPLICATIONS FOR UPHOLD LITE VAGINAL SUPPORT SYSTEM, XENFORM SOFT TISSUE REPAIR MATRIX.BOSTON SCIENTIFIC CORP - WILL WORK CLOSELY WITH FDA TO UNDERSTAND ITS DIRECTION AND DETERMINE NEXT STEPS.  Full Article

FDA Orders Manufacturers Of Surgical Mesh Intended For Transvaginal Repair Of Pelvic Organ Prolapse To Remove All Devices From The Market
Tuesday, 16 Apr 2019 

April 16 (Reuters) - U.S. Food and Drug Administration::FDA - ORDERS MANUFACTURERS OF SURGICAL MESH INTENDED FOR TRANSVAGINAL REPAIR OF PELVIC ORGAN PROLAPSE TO REMOVE ALL DEVICES FROM THE MARKET.FDA - DETERMINED MANUFACTURERS, BOSTON SCIENTIFIC & COLOPLAST, HAVE NOT DEMONSTRATED REASONABLE ASSURANCE OF SAFETY & EFFECTIVENESS FOR DEVICES.FDA - BOSTON SCIENTIFIC & COLOPLAST WILL HAVE 10 DAYS TO SUBMIT THEIR PLAN TO WITHDRAW PRODUCTS FROM THE MARKET.FDA - FOR MESH DEVICES TO STAY ON THE MARKET, DETERMINED THAT FDA NEEDS EVIDENCE THEY WORKED BETTER THAN SURGERY WITHOUT USE OF MESH TO REPAIR POP.  Full Article

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX Left Atrial Appendage Closure Device
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES CE MARK FOR NEXT GENERATION WATCHMAN FLX™ LEFT ATRIAL APPENDAGE CLOSURE DEVICE.BOSTON SCIENTIFIC-RECEIVED CE MARK, INITIATED A LIMITED MARKET RELEASE OF NEXT GENERATION WATCHMAN FLX(™) LEFT ATRIAL APPENDAGE CLOSURE DEVICE IN EUROPE.BOSTON SCIENTIFIC - BEGUN A LIMITED MARKET RELEASE OF WATCHMAN FLX DEVICE IN EUROPE, TO EXPAND COMMERCIALIZATION TO ADDITIONAL SITES IN H2 2019.  Full Article

Boston Scientific Completes $4.3 Billion Offering Of Senior Notes And Issues Redemption Notice For Its 2020 Notes
Tuesday, 26 Feb 2019 

Feb 25 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC COMPLETES $4.3 BILLION OFFERING OF SENIOR NOTES AND ISSUES REDEMPTION NOTICE FOR ITS 2020 NOTES.  Full Article

Boston Scientific Prices $4.3 Bln Of Senior Notes
Friday, 22 Feb 2019 

Feb 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PRICES $4.3 BILLION OF SENIOR NOTES.BOSTON SCIENTIFIC CORP - EXPECTS TO RECEIVE NET OFFERING PROCEEDS UPON CLOSING ON FEBRUARY 25, 2019.BOSTON SCIENTIFIC CORP SAYS PUBLIC OFFERING CONSISTS OF $850 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF 3.450% NOTES DUE 2024.BOSTON SCIENTIFIC CORP SAYS PUBLIC OFFERING CONSISTS OF $850 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF 3.750% NOTES DUE 2026.BOSTON SCIENTIFIC CORP SAYS PUBLIC OFFERING CONSISTS OF $850 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF 4.000% NOTES DUE 2029.BOSTON SCIENTIFIC CORP SAYS PUBLIC OFFERING CONSISTS OF $750 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF 4.550% NOTES DUE 2039.BOSTON SCIENTIFIC CORP SAYS PUBLIC OFFERING CONSISTS OF $1.000 BILLION IN AGGREGATE PRINCIPAL AMOUNT OF 4.700% NOTES DUE 2049..  Full Article

Boston Scientific Files Prospectus Supplement For A Potential Five-Part Senior Notes Offering
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORP FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL FIVE-PART SENIOR NOTES OFFERING - SEC FILING.  Full Article

Appaloosa Dissolves Stakes In Alibaba, Apple; Adds Allstate
Friday, 15 Feb 2019 

Feb 14 (Reuters) - Appaloosa LP::APPALOOSA TAKES SHARE STAKE IN ALLSTATE CORP OF 607,912 SHARES- SEC FILING.APPALOOSA DISSOLVES SHARE STAKE IN BOYD GAMING CORP.APPALOOSA DISSOLVES SHARE STAKE IN BOSTON SCIENTIFIC CORP.APPALOOSA DISSOLVES SHARE STAKE IN ALIBABA, APPLE- SEC FILING.APPALOOSA LP: CHANGE IN HOLDINGS ARE AS OF DECEMBER 31, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF SEPTEMBER 30, 2018.  Full Article

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC, EDWARDS LIFESCIENCES AGREE TO GLOBAL LITIGATION SETTLEMENT.BOSTON SCIENTIFIC CORP - ALL PATENT LITIGATION BETWEEN COMPANIES TO BE DISMISSED.BOSTON SCIENTIFIC CORP - EDWARDS HAS MADE A ONE-TIME PAYMENT TO BOSTON SCIENTIFIC OF $180 MILLION.BOSTON SCIENTIFIC CORP - ANY INJUNCTIONS CURRENTLY IN PLACE WILL BE LIFTED.BOSTON SCIENTIFIC CORP - NO FURTHER ROYALTIES WILL BE OWED BY EITHER PARTY UNDER AGREEMENT.BOSTON SCIENTIFIC CORP - CO & EDWARDS TO SETTLE ALL OUTSTANDING PATENT DISPUTES BETWEEN THEM.  Full Article

Boston Scientific sees $25 mln hit to 2019 revenue from mesh withdrawal

April 17 Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products.